Format

Send to

Choose Destination
J Trauma. 1998 Feb;44(2):361-7.

High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome.

Author information

1
Department of Anesthesiology and General Intensive Care, General Hospital (AKH) of the University of Vienna, Austria.

Abstract

OBJECTIVE:

To investigate erythropoietin (EPO) production and the erythropoietic potency of recombinant human EPO in the multiple organ dysfunction syndrome.

DESIGN:

Randomized, prospective, controlled clinical trial.

MATERIALS AND METHODS:

Patients received either 600 IU/kg intravenous EPO three times weekly (n = 9) or saline (control, n = 10).

MEASUREMENTS:

EPO levels, circulating soluble receptors for tumor necrosis factor and interleukin-2, levels of interleukin-6 and intercellular adhesion molecule, and early peripheral blood cell progenitors.

RESULTS:

EPO production in the control group remained low. Pharmacologic EPO blood levels were associated with increased reticulocyte counts compared with both controls (p < 0.04) and baseline (p < 0.006). Increased levels of soluble receptors for tumor necrosis factor in the treatment group compared with the controls did not prevent this effect. Interleukin 6 inhibited reticulocyte production.

CONCLUSION:

Despite increased cytokine levels, pharmacologic EPO blood levels were associated with increased reticulocyte counts in patients with multiple organ dysfunction syndrome.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center